NCT06488222View on ClinicalTrials.gov

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 5, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Bladder Cancer
Interventions
DRUG

Docetaxel

Subjects will receive 40 mg docetaxel intravesically.

DRUG

Gemcitabine

Subjects will receive 1 mg gemcitabine intravesically.

Trial Locations (1)

32608

RECRUITING

University of Florida, Gainesville

All Listed Sponsors
lead

University of Florida

OTHER